Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks
- Approval will broaden the NARCAN
®Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN
“At Emergent, we work closely with our partners to develop solutions that help improve delivery, distribution and accessibility of NARCAN
This approval builds on Emergent's ongoing commitment to enhancing NARCAN
About NARCAN
NARCAN
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Glassnode says institutional cash-and-carry trades are influencing US spot bitcoin ETF flows
Meta’s “Life-or-Death Lawsuit” Begins Today: 29 State Attorneys General Join Forces to Hold Them Accountable, Defeat Could Lead to $1.4 Trillion “Sky-High” Fine
The lawsuit alleges that Facebook and Instagram were deliberately designed as "addictive products," causing harm to tens of millions of underage users. Meta has estimated its maximum potential fine exposure at $1.4 trillion, nearly matching its current market capitalization. Mark Zuckerberg will personally testify in court, and the verdict may reshape the entire business model of the social media industry.
U.S. Human Resource Stocks Strongly Rebound: AI Resume Boom Makes Recruitment Companies Even More Valuable!
AI has not disrupted the US recruitment industry; instead, the proliferation of AI-generated resumes has increased the value of screening, creating new demand for HR companies. Recruitment stocks such as ManpowerGroup and Robert Half have reported better-than-expected earnings, with their share prices rebounding strongly from lows. AI has also become an efficiency tool for the industry, but valuations are under pressure after the rebound. The long-term trend will depend on the recovery of the US labor market and whether recruitment companies can truly benefit from AI.
3 Promising AI Cryptos to Accumulate Right Now — RNDR, FET, ICP

